### ü´† Cardiovascular Testing: Medication Management Before Stress Echocardiography

#### ‚úÖ True Statements
1. The decision to withhold **cardiac medications** before **exercise or pharmaceutical stress testing** should be **tailored to individual patient circumstances**.
2. If the indication for stress testing is to assess **the efficacy of current therapy** in a patient on **Œ≤-blockers** or **nitrates**, these medications **can be continued**.
3. Continuing **Œ≤-blockers** such as **carvedilol** allows evaluation of a patient‚Äôs **response to stress while on their usual medical regimen**.
4. **Caffeine** and other **methylxanthines** should be **withheld for 12 hours** before **vasodilator stress testing** with agents like **adenosine** or **regadenoson**.
5. It is **not necessary to withhold caffeine** before **exercise stress echocardiography**.
6. Holding **Œ≤-blockers** before a stress test may represent a **de-escalation of medical therapy** and is **not recommended** in patients with **stable angina** on **maximal medical therapy**.
7. Initiating a **long-acting nitrate** before stress testing may **mask ischemia** and is **not indicated**.
8. **Nitrates** are **contraindicated** in patients taking **phosphodiesterase type 5 inhibitors**, such as **sildenafil**.

#### üí¨ Extra
1. Medication management may vary depending on whether the test is for diagnosis, risk stratification, or assessment of treatment response.
2. This is particularly relevant when deciding if invasive coronary angiography is needed.
3. A prior adequate stress test while on therapy suggests current regimens do not prevent an appropriate heart rate response.
4. Methylxanthines block adenosine A2A receptors and may reduce vasodilator efficacy.
6. Stress test sensitivity is not meaningfully improved by withholding Œ≤-blockers in most patients.
7. Pharmacologic vasodilation or myocardial ischemia may not be appropriately unmasked if a nitrate is newly added.
8. Combining nitrates with PDE5 inhibitors may result in life-threatening hypotension.

#### üî∑ Tags
#Cardiology #AmbulatoryCare #StressTesting #BetaBlockers #IschemicHeartDisease #ExerciseTesting

#### üìô Reference
Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2021;144:e368-e454. PMID: 34709879 doi:10.1161/CIR.0000000000001029

#### üÜî Question ID
CVMCQ24023

#### üïí Last Updated
February 2025

---

#### üìñ Related Text
MKSAP 19: Cardiovascular Medicine ‚Äî Diagnostic Testing in Cardiology, Diagnostic Testing for Atherosclerotic Coronary Artery Disease, Cardiac Stress Testing

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. **Cardiac stress testing** is most effective in patients with an **intermediate pretest probability (10‚Äì90%)** of **coronary artery disease (CAD)**.
2. In patients with a **low pretest probability** of CAD, stress testing often results in **false-positive findings** and **unnecessary downstream testing**.
3. In patients with a **high pretest probability** of CAD, **invasive coronary angiography** may be more appropriate than stress testing.
4. **Exercise stress testing** is preferred over **pharmacologic stress testing** unless **exercise is contraindicated or not feasible**.
5. **Cardiac medications** that impair **heart rate response** (e.g., **Œ≤-blockers**) should be **withheld for 24 hours** before **diagnostic exercise stress testing** to improve sensitivity.
6. **Cardioactive medications** should be **continued** if the purpose of the test is to assess **symptom control**, **therapy efficacy**, or **prognosis** in patients with **known CAD**.
7. The ‚Äú**warranty period**‚Äù of a **normal, adequate stress test** is **1 year** in patients with unchanged symptoms.
8. **Achieving 85% of age-predicted maximal heart rate** or a **rate-pressure product ‚â•25,000** is considered an **adequate stress test workload**.
9. **Horizontal or downsloping ST-segment depression ‚â•1 mm** occurring **80 milliseconds after the J point** is indicative of **ischemia** on **exercise ECG**.
10. A **heart rate recovery <12 beats/min** in the first minute after exercise is associated with **increased mortality**.
11. The **Duke Treadmill Score** combines exercise duration, symptom development, and ST depression to estimate **5-year mortality** in patients without known CAD.
12. **Stress echocardiography** detects **new wall motion abnormalities** as indicators of **ischemia**, and persistent resting abnormalities may suggest **hibernating or infarcted myocardium**.
13. **Dobutamine stress echocardiography** aims to achieve **85% of age-predicted maximal heart rate**, with **atropine** used as needed.
14. In patients with **left bundle branch block (LBBB)** or **paced rhythm**, **exercise is preferred** over **dobutamine** stress echocardiography.
15. A **perfusion defect on SPECT imaging** that is present both **at rest and after stress** suggests an **infarct or hibernating myocardium**.
16. **Left ventricular (LV) dilation after stress** on **SPECT or stress echocardiography** with a normal resting study may indicate **balanced ischemia** or **multivessel coronary artery disease (CAD)**.
17. A **wall motion abnormality** induced by stress on **echocardiography**, in the setting of a **normal resting wall motion**, is indicative of **stress-induced myocardial ischemia**.
18. On **SPECT myocardial viability testing**, **reperfusion of a previously hypoperfused area** after delayed thallium rest imaging suggests **viable myocardium**.
19. A **biphasic response to dobutamine** on echocardiographic viability testing (improvement at low dose, worsening at high dose) is consistent with **viable myocardium**.
20. On **positron emission tomography (PET)** viability imaging, a **perfusion defect with preserved metabolic activity** indicates **viable myocardium**.

#### üí¨ Extra
1. Intermediate pretest probability is the optimal zone for influencing post-test probability.
2. Young patients with atypical chest pain often fall in this low-likelihood category.
3. Invasive angiography may be a better option when pretest probability is high and CAD is suspected.
4. Exercise testing provides functional and prognostic data not obtained with pharmacologic testing.
5. Œ≤-Blockers blunt the heart rate response, potentially leading to nondiagnostic testing.
6. Symptom-driven testing reflects real-world performance under therapy.
7. A normal stress test predicts low cardiac event risk for about 1 year.
8. Rate pressure product reflects myocardial oxygen demand and test adequacy.
9. ST-segment depression on stress ECG suggests myocardial ischemia, though it lacks localization.
10. Heart rate recovery is a marker of autonomic function and cardiovascular fitness.
11. The Duke Score stratifies patients into low, intermediate, or high risk of death.
12. Stress echo detects ischemia earlier than ECG alone and helps localize affected territories.
13. Atropine is added if maximal heart rate is not achieved with dobutamine alone.
14. LBBB causes baseline ECG and wall motion artifacts that may confound pharmacologic testing.
15. Fixed perfusion defects imply scarred, nonviable tissue, while hibernating myocardium may regain function after revascularization.
16. Balanced ischemia refers to uniform subendocardial ischemia that may not show focal perfusion defects.
17. Stress-induced wall motion abnormalities reflect regional myocardial dysfunction due to inadequate perfusion.
18. Thallium rest redistribution imaging evaluates delayed perfusion recovery to distinguish viable from infarcted tissue.
19. The biphasic response pattern is highly specific for identifying dysfunctional but recoverable myocardium.
20. Preserved glucose metabolism in areas of reduced perfusion on PET suggests myocardial hibernation rather than scar.

#### üî∑ Tags
#Cardiology #StressTesting #CAD #ExerciseECG #DukeTreadmillScore #BetaBlockers #DiagnosticEvaluation #AmbulatoryCare

---

#### üñºÔ∏è Supplemental Figure

<!--ECG Recorded at Baseline (Left) and During Exercise Stress Testing (Right)-->
<figure>
  <img src="ECG Recorded at Baseline (Left) and During Exercise Stress Testing (Right).jpg" alt="Exercise ECG showing ischemia">
  <figcaption>
    <strong>ECG Recorded at Baseline (Left) and During Exercise Stress Testing (Right)</strong><br>
    The presence of **2-mm downsloping ST-segment depressions** in **leads I to III, aVF, and V3 to V6** during exercise is **diagnostic of ischemia** but does **not localize a specific coronary distribution**.
  </figcaption>
</figure>

<!--Nuclear Perfusion Single-Photon Emission CT Stress Study-->
<figure>
  <img src="Nuclear Perfusion Single-Photon Emission CT Stress Study.jpg" alt="Nuclear Perfusion SPECT Stress Study">
  <figcaption>
    <strong>Selected Images From a Nuclear Perfusion Single-Photon Emission CT Stress Study</strong><br>
    Normal perfusion is indicated by orange to white coloring, whereas poor perfusion is indicated by purple to blue coloring.<br>
    <strong>Panel A (short-axis views):</strong> Stress images (top row) show a radiotracer defect in the septal, anterior, and inferior walls that is filled on the rest images (bottom row).<br>
    <strong>Panel B (long-axis views):</strong> Stress images (top row) demonstrate anterior, apical, and inferior filling defects that are perfused at rest (bottom row).<br>
    These findings are consistent with <strong>reversible myocardial ischemia</strong>.
  </figcaption>
</figure>

---

#### üóæ Supplemental Tables

<!-- Table 1: Interpretation of Stress Testing With Imaging Results -->
<table>
  <caption><strong>Interpretation of Stress Testing With Imaging Results</strong></caption>
  <thead>
    <tr>
      <th colspan="3">Stress SPECT</th>
    </tr>
    <tr>
      <th>At Rest</th>
      <th>After Stressor</th>
      <th>Interpretation</th>
    </tr>
  </thead>
  <tbody>
    <tr><td>Normal</td><td>Normal</td><td>Normal</td></tr>
    <tr><td>Normal</td><td>Perfusion defect</td><td>Stress-induced myocardial ischemia</td></tr>
    <tr><td>Perfusion defect</td><td>Same perfusion defect</td><td>Infarct or hibernating myocardium</td></tr>
    <tr><td>Normal</td><td>LV dilation</td><td>Small or no distinct zone of ischemia, possible balanced ischemia or multivessel CAD</td></tr>
  </tbody>
</table>
<table>
  <thead>
    <tr>
      <th colspan="3">Stress Echocardiography</th>
    </tr>
    <tr>
      <th>At Rest</th>
      <th>After Stressor</th>
      <th>Interpretation</th>
    </tr>
  </thead>
  <tbody>
    <tr><td>Normal</td><td>Normal</td><td>Normal</td></tr>
    <tr><td>Normal</td><td>Wall motion abnormality</td><td>Stress-induced myocardial ischemia</td></tr>
    <tr><td>Regional wall motion abnormalities</td><td>Same regional wall motion abnormalities</td><td>Infarct or hibernating myocardium</td></tr>
    <tr><td>Normal</td><td>LV dilation</td><td>Small or no distinct zone of ischemia, possible balanced ischemia or multivessel CAD</td></tr>
  </tbody>
</table>
<p><em>CAD = coronary artery disease; LV = left ventricular; SPECT = single-photon emission CT.</em></p>

<!-- Table 2: Interpretation of Myocardial Viability Study Results -->
<table>
  <caption><strong>Interpretation of Myocardial Viability Study Results</strong></caption>
  <thead>
    <tr>
      <th colspan="3">SPECT Viability Testing</th>
    </tr>
    <tr>
      <th>Initial Study (at Rest)</th>
      <th>Rest Study Repeated After 4‚Äì24 h (With Thallium)</th>
      <th>Interpretation</th>
    </tr>
  </thead>
  <tbody>
    <tr><td>Perfusion defect</td><td>Perfusion defect</td><td>Fixed defect: infarct, no viability</td></tr>
    <tr><td>Perfusion defect</td><td>Reperfusion of area</td><td>Viable myocardium</td></tr>
  </tbody>
</table>
<table>
  <thead>
    <tr>
      <th colspan="3">PET Viability Testing</th>
    </tr>
    <tr>
      <th>Baseline</th>
      <th>Metabolism</th>
      <th>Interpretation</th>
    </tr>
  </thead>
  <tbody>
    <tr><td>Perfusion defect</td><td>Metabolically active</td><td>Viable myocardium</td></tr>
  </tbody>
</table>
<table>
  <thead>
    <tr>
      <th colspan="3">Echocardiographic Viability Testing</th>
    </tr>
    <tr>
      <th>Baseline</th>
      <th>Response to Dobutamine</th>
      <th>Interpretation</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Wall motion abnormality</td>
      <td>Low dose: improvement of function<br>Higher dose: worsening of function</td>
      <td>Biphasic response indicates viable myocardium</td>
    </tr>
  </tbody>
</table>
<p><em>SPECT = single-photon emission CT.</em></p>